HANSHOW
8.6.2021 04:02:06 CEST | Business Wire | Press release
Deploying scalable and affordable enterprise grade IoT applications in the retail industry has previously been restricted by technology limitations. But digital retail solutions leader Hanshow has now developed a SaaS solution that accelerates this digital transformation by connecting store shelves to retailers, store operators, and customers on an unprecedented scale by managing more than 10 million IoT devices across a vast network of Ahold Delhaize stores in Europe.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210607005244/en/
Ahold Delhaize and Hanshow began partnering in 2018 to install electronic shelf labels (ESL) and other digital solutions at select stores in Europe. This later expanded to cover hundreds of stores across Europe and over 10 million ESL – a tremendous number of devices to sync and manage.
ESLs are the building blocks of retail digitization, and effective solutions for connecting them are crucial to maximize efficiency and open up new digital solution possibilities. However, the ability to remotely manage tens of millions of ESL across hundreds of stores through one cloud-based network had not yet been possible until Hanshow partnered with Microsoft to develop a SaaS solution that can handle this massive amount of integration.
Adopting solutions through cloud services and IoT technology is rapidly growing in retail. Global research firm Gartner estimates, “Worldwide end-user spending on public cloud services is forecast to grow 18.4% in 2021 to total $304.9 billion, up from $257.5 billion in 2020”.* It further adds, “Although software as a service (SaaS) remains the largest market segment and is forecast to grow to $117.7 billion in 2021, application infrastructure services (PaaS) is anticipated to grow by a higher margin at 26.6%” *
The benefits of adopting such services are apparent through this partnership. The Hanshow SaaS solution addresses a number of challenges for retailers such as staffing surges during peak times, labor costs, space constraints, and overall productivity.
Under previous scenarios, retailers have to install and operate their own system of servers and infrastructure on premise requiring a massive investment, untold time to set up, and significant input from IT professionals.
The Hanshow SaaS Solution provides global retailers an intelligent, easy-to-deploy, user-friendly, and analytics driven platform. Hanshow SaaS is ready on arrival and can be accessed instantly anytime, anywhere. Data can be shared across geographies while remote monitoring and updates become a seamless exercise. Price updates and other ESL or digital solution updates can be done at breakneck pace; 3 million ESL can be updated in just 80 min. And with a focus on the heightened security needed from a cloud-based network, Hanshow carried out third-party security testing through a leading global security firm to certify data safety of the Microsoft Azure backed Hanshow SaaS.
“This scale and advancement in retail technology was made possible through the safety, stability, scalability and speed of Microsoft SaaS with Hanshow’s innovative management software,” said Raj Raguneethan, regional leader, Retail & Consumer Goods at Microsoft Asia. “With this work, we’re seeing only the beginning of what’s possible with IoT and SaaS.”
While over 10 million ESL have already integrated into the Hanshow SaaS, it can handle much more if necessary. “By integrating retail digitization with SaaS, the possibilities are endless,” said Hanshow Executive Chairman and CEO Shiguo Hou. “This is the future. We're committed to bringing these benefits to customers and retailers on an even grander scale.”
*Gartner Press Release, “Gartner Forecasts Worldwide Public Cloud End-User Spending to Grow 18% in 2021”, 17 November 2020, [https://www.gartner.com/en/newsroom/press-releases/2020-11-17-gartner-forecasts-worldwide-public-cloud-end-user-spending-to-grow-18-percent-in-2021 ]
About Hanshow
Hanshow is a global leader in developing and manufacturing electronic shelf labels and digital store solutions. As an innovation leader in the industry, Hanshow is dedicated to offering its global customers a series of world-class customized IoT touchpoints and digital store solutions. Hanshow’s intelligence-enabled platforms and systems deliver customer-centric insights, helping retailers streamline operations and providing various solutions to support optimal pricing strategies to offer consumers a more personalized experience. Hanshow currently serves over 20,000 stores in more than 50 countries. For more information, please visit www.hanshow.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210607005244/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
